Agenus is a clinical-stage immuno-oncology company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in trials of balstilimab monotherapy and balstilimab/zalifrelimab combination for patients with second-line cervical cancer. Co. is also developing its proprietary anti-CTLA-4 antibody, AGEN1181, which is designed to expand the population of patients benefiting from anti-CTLA-4 therapy. Co.'s AgenTus Therapeutics, Inc. subsidiary focuses on allogeneic cell therapies. We show 37 historical shares outstanding datapoints in our coverage of AGEN's shares outstanding history.
Understanding the changing numbers of AGEN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AGEN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AGEN by allowing them to research AGEN shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
